Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models

被引：0
|
作者：
Ichikawa, Kenji [1 ]
Miyano, Saori Watanabe [1 ]
Minoshima, Yukinori [1 ]
Matsui, Junji [1 ]
Funahashi, Yasuhiro [1 ]
机构：
[1] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-196
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页数：2
相关论文
共 50 条
  • [31] RNA aptamers with anti-VEGF, anti-angiogenic and anti-prostate tumor activity
    Zhang, S
    Cheng, L
    Xu, W
    Dominguez, J
    MODERN PATHOLOGY, 2002, 15 (01) : 188A - 188A
  • [32] The impact of primary tumor site and anti-VEGF therapy in metastatic colorectal cancer
    Ana, Pissarra
    Mariana, Malheiro
    Andreia, Coelho
    Ana, Placido
    Ana, Martins
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Radiation enhances anti-tumor activity of immune checkpoint blockade in syngeneic tumor models
    Urs, Sumithra
    Meade, Mary Anne
    Guley, Kevin
    Krueger, Sarah
    Wong, Alden
    Wise, Scott
    Franklin, Maryland
    CANCER RESEARCH, 2018, 78 (13)
  • [34] The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
    Ozawa, Y.
    Kuronishi, M.
    Kato, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S363 - S363
  • [35] Anti-tumor effects of lenvatinib plus anti-PD-1 in syngeneic murine cervical cancer models
    Park, Su-Bin
    Kang, Ji-Sik
    Kim, Min-Je
    Lee, Shin-Wha
    Kang, Dong-Woo
    Kim, Yong-Man
    CANCER RESEARCH, 2022, 82 (12)
  • [36] In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies
    Denis, Morgane
    Grasselly, Chloe
    Choffour, Pierre-Antoine
    Wierinckx, Anne
    Mathe, Doriane
    Chettab, Kamel
    Tourette, Anne
    Talhi, Nolan
    Bourguignon, Aurore
    Birzele, Fabian
    Kress, Elsa
    Jordheim, Lars Petter
    Klein, Christian
    Matera, Eva-Laure
    Dumontet, Charles
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (08) : 1013 - 1027
  • [37] Tumor refractoriness to anti-VEGF therapy is mediated by myeloid cell recruitment in malignant melanoma
    Helfrich, I.
    Stockmann, C.
    Middleton, M.
    Schadendorf, D.
    EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e45 - e45
  • [38] Less tumor engraftment after anti-VEGF therapy in pediatric low grade astrocytoma
    Sie, Mariska
    Sikkema, Arend H.
    Scherpen, Frank J. G.
    ter Elst, Arja
    Kampen, Kim R.
    Hoving, Eelco W.
    den Dunnen, Wilfred F. A.
    de Bont, Eveline S. J. M.
    CANCER RESEARCH, 2013, 73 (08)
  • [39] SYNERGISTIC ANTITUMOR-ACTIVITY OF INTERLEUKIN-2 AND CIMETIDINE AGAINST SYNGENEIC MURINE TUMOR
    NAKAJIMA, I
    CHU, TM
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (01) : 9 - 14
  • [40] Evaluation of the antitumor activity and molecular characterization of mouse syngeneic tumor models in response to anti-PD-1 treatment as a single agent and in combination with approved agents
    Hirsch, Heather
    Mangadu, Ruban
    Cai, Mingmei
    Ma, Yanhong
    Phan, Uyen
    Wang, Yaolin
    Sriram, Venkataraman
    Phillips, Joseph H.
    McClanahan, Terri
    Long, Brian
    Pinheiro, Elaine M.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
12345